IXICO plc
(“IXICO”, the “Company” or the “Group”)
£2.7 million Phase 3 contract win in Huntington’s disease
02 November 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today announced that it has won a global Phase 3 clinical trial contract in Huntington’s disease (HD) with an international biotechnology company. The contract is worth £2.7million in revenues to IXICO over the next six years.
This is the second Phase 3 HD contract that IXICO has been awarded over the past 12 months, reinforcing its position as a trusted partner to biopharma companies as an increasing number of innovative new therapies in HD advance to late stage clinical trials and potential FDA approval. The news follows the announcement in late October of two contract wins in Alzheimer’s Disease (AD) and sees a continuation of IXICO’s revenue growth momentum and order book expansion.
Bram Goorden, CEO of IXICO, commented: “We are proud to be working at the cutting edge of innovative therapies, helping biopharmaceutical companies advance potentially transformative treatments for patients and families affected by Huntington’s disease. This contract is another strong endorsement of IXICO’s leading position in the neurodegenerative disease field. It also demonstrates our continued progress in strengthening our order book through an increasing contribution from later-stage clinical trials, providing long-term revenue visibility and supporting our growth ambitions.”
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the platform and IXICO’s expert scientists translating complex data into clinically meaningful insights while minimizing data variability and increasing reproducibility.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.